SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to the company's earnings report, which included a significant one-time tax charge and forecasts of increased capital expenditures for AI development. The community is debating whether this decline presents a buying opportunity or signals concerns about future profitability and spending discipline. Some believe the market is overreacting to a non-recurring event, while others worry about the long-term implications of Meta's aggressive AI investments.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Fueled by growing anticipation for its upcoming earnings report, GOOG is trending as the community discusses the potential impact of AI advancements and cloud services on its revenue. Positive sentiment is building around Google's core businesses, with some analysts raising price targets ahead of the report. Traders are also closely watching for updates on Google's AI strategy and partnerships, particularly regarding quantum computing.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to after-hours momentum and a low float, sparking community interest in a potential short squeeze. Discussions revolve around its potential to reach higher price levels, with some comparing it to other recent high-flying stocks. However, caution is advised as some traders are calling it a pump and dump scheme.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors digest mixed reactions to earnings, with revenue and EPS exceeding expectations but Azure growth guidance causing concern. Community discussions revolve around the impact of increased AI spending and its potential dilution, alongside anticipation for analyst upgrades. The broader market context involves mega-cap tech earnings and geopolitical factors influencing trade.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending downwards after disappointing earnings and lowered guidance, with concerns about declining customer traffic and macroeconomic pressures. The community is discussing whether the stock is oversold and if a significant bounce is likely. Many express concerns about high prices, reduced portion sizes, and declining food quality impacting the brand's popularity.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending due to a mix of political and economic factors, including discussions around Trump's policies and their impact on various sectors. Community members are debating the potential effects of tariffs, trade deals, and government actions on market stability and individual companies. There's also active discussion about the Federal Reserve's interest rate decisions and their implications for future economic growth.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending after a surprise Q3 profit and upgraded guidance sparked bullish sentiment among retail traders. The community is focused on a potential short squeeze, with some anticipating a re-rating of the stock. Optimism is fueled by discussions of debt repayment, potential buyouts, and the company's future revenue prospects.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending amid discussions of its recent $900M convertible note offering and its implications for dilution and growth, with community members debating the bullish and bearish interpretations of the financing structure. Bullish sentiment highlights the potential for expansion in AI and data centers, while bears focus on the risk of short-term price decline. The conversation also includes speculation around potential partnerships with major players like Google.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the 'Bitcoin of memes,' sparking excitement about its potential within the crypto space; the community rallies behind the narrative that 'We are all Satoshi.' Anticipation is building for upcoming events that could further propel the token's visibility and adoption.

Sprouts Farmers Market, Inc. engages in the operation of healthy grocery stores. The firm specializes in fresh, natural and organic products. Its products include fresh produce, bulk foods, vitamins and supplements, grocery, meat and seafood, deli, bakery, dairy, frozen foods, body care and natural household items. The company was founded by Stan Boney, Shon Alexander Boney, and Kevin K. Easler on July 11, 2002 and is headquartered in Phoenix, AZ.

Sprouts Farmers Market Inc

Sprouts Farmers Market is trending as the community discusses the recent share repurchase authorization of $1 billion. While some investors see this as a bullish signal and buying opportunity, others express concerns about lowered guidance and potential challenges ahead for the grocery chain, drawing comparisons to sector averages. The debate centers on whether the buyback will offset concerns about the company's growth prospects and valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to a CNBC report, the price of the product, known as Quark AI Glasses, during pre-sale would be at 4,699 yuan.</li><li>The report added that Alibaba will begin shipping the product&nbsp;in December.</li><li>The eyewear would help with a variety of tasks, including hands-free calling, music streaming, and real-time language translation, the report said.</li></ul>Alibaba (BABA) has reportedly announced the price of its soon-to-launch artificial intelligence glasses, which would go on pre-sale on October 24 on its e-commerce platform Tmall.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/10/23/alibaba-prices-ai-glasses-at-660-and-launches-chatgpt-rival.html">CNBC report</a> on Thursday, the price of the product, known as Quark AI Glasses, during pre-sale would be at 4,699 Chinese yuan ($659.4), and after applying several discounts, it would cost 3,999 yuan.The report added that Alibaba will begin shipping the product&nbsp;in December. U.S.-listed shares of Alibaba rose nearly 2% in premarket trading on Thursday.<h2 class="st-heading-2">Quark AI Glasses</h2>The CNBC report noted that Alibaba had first unveiled the Quark AI Glasses launch in July. It was one of the first products of its kind from Alibaba, and the glasses use the company’s Qwen large language model and its Quark AI assistant, it said.The report added that the eyewear would help with a variety of tasks, including hands-free calling, music streaming, and real-time language translation.CNBC reported that the Quark AI glasses are competing with Meta Platforms (META) smart glasses, which are made in collaboration with Ray-Ban.&nbsp;With the launch of Quark AI glasses, Alibaba will compete with another China-based consumer electronics player, Xiaomi, which unveiled its AI glasses this year, the report said.<h2 class="st-heading-2">AI Chat Assistant In Quark App</h2>Alibaba said it has launched advanced AI chat features in its Quark app as part of its plans to reach more individual users.&nbsp;Quark's chat feature enables users to communicate via text or voice, leveraging Alibaba’s advanced Qwen3 models. According to the company, the feature delivers improved reasoning, understanding, and task-handling performance.Retail sentiment on Alibaba remained unchanged in the ‘bearish territory, with message volumes at ‘low’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/BABA">U.S.-listed shares of Alibaba</a> have gained over 95% this year.1 Chinese Yuan = $0.14For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-puts-ai-chat-in-quark-app-eyes-consumers-in-latest-growth-push/cLG4ayxR3AL">Alibaba Puts AI Chat In Quark App, Eyes Consumers In Latest Growth Push</a>

2025/07/18: The "Alibaba" logo on a blue background at the 3rd China International Supply Chain Expo. 

Alibaba’s AI Glasses To Be Priced At $659, Pre-Sale Planned On October 24 Via Its E-commerce Platform Tmall: Report

According to a CNBC report, the price of the product, known as Quark AI Glasses, during pre-sale would be 4,699 yuan.

Equity

AstraZeneca (AZN) on Wednesday announced the unveiling of its expanded manufacturing facility in Texas aimed at doubling the production of its drug Lokelma.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251014866366/en/AstraZeneca-unveils-expanded-manufacturing-facility-in-Texas">invested</a> $445 million to expand the facility, it said. The unveiling <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-announces-4.5-billion-dollar-investment-in-virginia/ch67yQKR31I">follows</a> the groundbreaking last week at the drugmaker’s $4.5 billion manufacturing facility in Albemarle County, Virginia. &nbsp;The investments are part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then.The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for AstraZeneca’s Lokelma, a prescription medicine for the treatment of high levels of potassium in the blood in adults, a condition known as hyperkalemia.The facility supplies the drug to more than 50 countries worldwide. <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a> said that through the expansion and development of a new 9,000 square foot building, two novel manufacturing lines will be added, along with enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities, and administrative space.The increased investment in the U.S. by drugmakers follows President Donald Trump’s push to move pharmaceutical manufacturing to American soil. Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products effective October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.On Stocktwits, retail sentiment around AZN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.AZN stock is up by 29% this year and by about 8% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 

Drugmaker AstraZeneca (AZN) on Thursday said that it will invest $4.5 billion in a new manufacturing facility in Virginia amid President Donald Trump’s push to move pharmaceutical manufacturing to American soil.The investment is $500 million more than initially planned and is intended to support the enhanced manufacturing capability of a broader range of medicines, including weight management, metabolic, and cancer technologies, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251009456597/en/AstraZeneca-plans-to-increase-investment-and-scope-of-its-Virginia-manufacturing-facility-to-%244.5-billion-creating-3600-new-jobs">said.</a>The new facility will be located at Rivanna Futures in Albemarle County, and the company expects the facility to create 600 skilled jobs and an additional 3000 jobs to support the facility’s construction. The construction will start immediately, and the facility is expected to be operational in the next four to five years, the company added.The new announcement is part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then. AstraZeneca CEO Pascal Soriot on Thursday noted that the investment in Virginia is the largest in the company’s history.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume dropped from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:996/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_1_46_59_PM_png_5e85c683cb.webp" alt="AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="996" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.Last month, AstraZeneca <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-plans-ordinary-share-listing-in-us/chDub9CR376">announced</a> that it plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq. The move is part of the company’s efforts to expand its access to capital, it had said, while noting that the U.S. has the world’s largest and most liquid public markets by capitalization.AZN stock is up by 31% this year and by 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-intends-to-launch-longer-range-model-y-variant-in-china/ch67xJOR315">Tesla Reportedly Intends To Launch A Longer Range Model Y Variant In China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Announces $4.5B Investment In Virginia 

The investment is $500 million more than initially planned, intended to support the enhanced manufacturing capability of a broader range of medicines, according to the company. 

AstraZeneca (AZN) plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq, the pharmaceutical giant announced on Monday.The move is part of the company’s efforts to expand its access to capital, including in the U.S. Nasdaq-listed ADRs of the company traded 1% higher in the pre-market session at the time of writing.Following the implementation of the new and harmonized listing structure, shareholders will be able to trade their interests in AstraZeneca ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE), the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-harmonise-its-listing-structure-across-the-london-stock-exchange-nasdaq-stockholm-and-new-york-stock-exchange.html">said</a>.Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders, while remaining headquartered in the U.K. The plan will now be put to a vote on November 3.On Stocktwits, retail sentiment surrounding <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> remained within the ‘bearish’ territory while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:578/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_6_49_19_AM_png_073b67d335.webp" alt="AZN's Sentiment Meter and Message Volume as of 6:49 a.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="578" height="62"><figcaption>AZN's Sentiment Meter and Message Volume as of 6:49 a.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>AstraZeneca stated that the U.S. has the world’s largest and most liquid public markets by capitalization. The new listing structure will not alter the company’s status as a U.K.-listed, headquartered, and tax-resident company, the company added.In 2024, the United States accounted for 43% of AstarZeneca’s total revenue. The U.S. accounted for $23.23 billion in revenue while Europe accounted for 23% of total revenue, or $12.19 billion.In July, the company also announced a $50 billion investment in the U.S. by 2030, which would include the expansion of its research and development facility in Maryland, as well as manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California, among others.It had then stated that the investments would help it achieve its goal of reaching $80 billion in total revenue by 2030, with half of that revenue to be generated in the U.S. AZN shares are up by 13% this year but down by over 5% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-closes-probe-into-stellantis-24000-alfa-romeo-vehicles/chDM6PoR37x">US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Plans Ordinary Share Listing In US – Find Out More On The Harmonized Listing Structure

Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders. 

The National Highway Traffic Safety Administration (NHTSA) announced on Monday that it has closed its investigation into approximately 24,000 model year 2017-2018 Alfa Romeo Giulia vehicles.The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures in certain Alfa Romeo Giulia vehicles. During its investigation, the NHTSA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24003-86036.pdf">determined</a> that the vehicles were equipped with fuel delivery pumps supplied by Vitesco Technologies Germany GmbH.However, Stellantis issued a recall earlier this month covering 29,467 model-year 2017–2019 Alfa Romeo Giulia vehicles and 24,382 model-year 2018 Alfa Romeo Stelvio vehicles, all equipped with the suspect Vitesco fuel delivery pump. A remedy is under development, the company said.The NHTSA stated that it is closing its probe in light of the recall issued by Stellantis. However, the regulator said it reserves the right to take additional action if warranted.The NHTSA also noted that it is aware of 1,900 vehicles experiencing failures related to the issue, adding that it is aware of one crash associated with the issue, but no injuries, fatalities, or fires.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> remained within ‘bearish’ territory while message volume remained at ‘high’ levels.The NHTSA also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24006-86034.pdf">announced </a>on Monday that it has closed a probe into 226,250 model year 2018-2020 Dodge Journey vehicles, which was initiated in February 2024 due to complaints regarding the backup camera function. The company recently issued a recall to resolve the issue and noted that it will replace defective cameras in the recalled vehicles with an updated part that resolves the problem.STLA stock is down 29% this year and approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Alfa Romeo Giulia on display at the Edmonton Motor Show on April 13, 2025, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles

The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures. 

The U.S. Food and Drug Administration has sent a letter to Novo Nordisk (NVO) CEO Maziar Mike Doustdar regarding the company’s promotional communication featuring Oprah Winfrey, alleging that the video is false or misleading.The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024. It also subsequently appeared on Hulu. The video is a 42-minute special program hosted by Oprah Winfrey, featuring patient testimonials from individuals who struggle with obesity and excessive weight, including those who have used Novo’s Wegovy, Ozempic, or Victoza.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025">alleged</a> in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. The video was also not submitted at the time of initial dissemination or publication as required by law, the agency said.“These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks,” the agency said.The FDA also noted that obesity and type 2 diabetes are significant public health concerns in the U.S., and consumers who seek medical treatment for these conditions should receive truthful and nonmisleading information regarding the serious risks associated with the use of the drugs. While Novo’s Wegovy is used for weight management, its Ozempic and Victoza are used to treat type 2 diabetes.The FDA said that several advisory comments dated as long back as 2010 addressed draft promotional communications for Victoza with certain similarities to the aforementioned video. The agency expressed concerns that <a href="https://stocktwits.com/symbol/NVO">Novo</a> is promoting the three drugs in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite the FDA’s prior comments.While the video includes numerous representations of the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, it omits important risk information or minimizes the risks associated with these drug products, the FDA said. Only four minutes in total were devoted to the important risks associated with GLP-1 drugs, such as Wegovy, the FDA said.The video also omits reference to how the drugs are contraindicated in patients with a personal or family history of Medullary Thyroid Cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2, it added. The omissions are exacerbated by statements from Amanda Velazquez, a paid consultant of Novo, made on the video, the FDA said.NVO stock is down by 33% this year and by 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">Hims &amp; Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ 

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 

Novo Nordisk (NVO) announced on Tuesday that its new obesity treatment, Cagrilintide, reduced body weight by 11.8% after 68 weeks in a late-stage study.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916427">reported</a> an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in the trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity or overweight and a weight-related comorbidity without diabetes. The above levels of weight reduction were observed in participants who adhered to the treatment. Regardless of adherence, average weight loss with Cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_9_59_21_AM_png_2efadb4b5b.webp" alt="NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment that the stock rallied only 2-3% on good news.<stembedurl>https://stocktwits.com/King990/message/628811943</stembedurl>Cagrilintide works differently from currently approved GLP-1-based treatments for weight loss, including Novo’s Wegovy and Eli Lilly’s Zepbound. The new drug mimics the naturally occurring hormone amylin that helps control blood glucose levels and appetite by slowing gastric emptying, reducing glucagon secretion, and promoting satiety.The company also stated that approximately one in three participants receiving Cagrilintide achieved 15% or more weight loss, compared to approximately one in 20 participants receiving a placebo, when patients adhered to the treatment.Novo stated that the drug was well-tolerated, while adding that the most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These side effects were mainly temporary and mild to moderate, and 1% of participants discontinued the study due to nausea, compared to 0.1% of participants who received a placebo.“We’re excited that these data, the first phase 3 data of a next-generation amylin therapy, show promise, and we look forward to further investigating cagrilintide’s potential in the dedicated phase 3 RENEW programme,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.Another late-stage programme investigating the efficacy and safety of Cagrilintide in people with obesity or overweight is due to start in the fourth quarter of this year.Separately, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://bloomberg.com/news/articles/2025-09-16/novo-plans-to-seek-us-approval-for-its-high-dose-obesity-shot?sref&amp;#61;8QBk7toa">reported</a> on Tuesday that Novo plans to seek U.S. regulatory approval for a high-dose version of Wegovy. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for the U.S. Food and Drug Administration approval, said Lange at the European Association for the Study of Diabetes conference in Vienna, according to the report.NVO stock is down 34% this year and by about 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-probe-into-174000-plus-tesla-model-y-vehicles/chwyiNgRdz5">US Regulator Opens Probe Into 174,000-Plus Tesla Model Y Vehicles – Check Out Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-Stage Study

The company reported an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in a trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy. 

Automaker Stellantis NV (STLA) is recalling 53,849 vehicles in the U.S. over concerns that the fuel pump may fail, U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) said on Tuesday.The NHTSA <a target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V586-8785.pdf">noted</a> that a fuel pump failure can result in a loss of fuel flow and drive power, increasing the risk of a crash. The recall includes model year 2017-2019 Alfa Romeo Giulia and model year 2018-2019 Alfa Romeo Stelvio vehicles. Some of the vehicles may have been built with a fuel delivery module (FDM) that contains internal components susceptible to heat, resulting in a loss of flow rate and, consequently, a reduction in motive power, it said. &nbsp;The remedy for the issue is currently under development. While letters notifying vehicle owners of the safety risk are expected to be mailed by the end of October, letters regarding the remedy will be sent once it becomes available, it added.The NHTSA noted that the recall follows an investigation initiated in January 2024. Stellantis has identified 437 customer complaints and field reports in North America that are potentially related to the issue. The company is also aware of five crashes and three injuries potentially related to the issue across all markets, it said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:580/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_7_09_28_AM_png_0b39e79559.webp" alt="STLA's Sentiment Meter and Message Volume as of 7:09 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="580" height="59"><figcaption>STLA's Sentiment Meter and Message Volume as of 7:09 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes for a rally this week, with the stock touching $10.<stembedurl>https://stocktwits.com/BullRunx100/message/628744748</stembedurl>STLA stock is down by about 26% this year and by about 37% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bloom-energy-stock-jumped-7-this-morning/chwyhXlRdyC">Bloom Energy Stock Jumped 7% This Morning – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stellantis Recalls Nearly 54,000 Vehicles In US Over Concerns Regarding Fuel Pump: But Retail Sees Stock Rallying To $10 This Week

The recall includes model year 2017-2019 Alfa Romeo Giulia and model year 2018-2019 Alfa Romeo Stelvio vehicles.

Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly expected to launch oral obesity pills by next year once they get regulatory approval in the U.S.According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. Daily pills would likely bring GLP-1s to more people, the report stated.&nbsp;The report noted that the primary aim of the study is to assess the effectiveness of the pills in lowering blood sugar levels in individuals with Type 2 diabetes, while also monitoring their impact on weight loss.“We wouldn’t have undertaken this head-to-head phase three randomized control trial unless we had a lot of confidence that orforglipron would fare well in comparison to oral semaglutide,” Skovronsky told CNBC.Retail sentiment on <a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to Stocktwits data.The report said that Skovronsky noted the results across trials, which did not directly compare the two drugs, should not be made, given Novo’s pill appears more effective with fewer discontinuations.&nbsp;Meanwhile, Novo’s Chief Scientific Officer, Martin Holst Lange, told CNBC in another interview that the data speaks for itself.Retail sentiment on <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained in the ‘bearish’ territory, with chatter at ‘low’ levels, according to data from Stocktwits.The report explained that Novo’s upcoming obesity pill is a tablet form of its weekly injection, Wegovy. In contrast, Lilly’s pill, Orforglipron, is a completely new drug and different from its injectable treatment, Zepbound. According to Skovronsky, Zepbound remains the benchmark for effectiveness, helping patients lose over 20% of their body weight.The CNBC report noted that neither Novo’s pill nor Lilly’s oral drug is as effective as Zepbound. It added that Orforglipron&nbsp;has achieved around 12% weight loss at its highest dose, while oral Semaglutide&nbsp;has reached about 17%, prompting uncertainty over how many patients will choose a pill if it delivers less weight loss than injectable options.Skovronsky told CNBC that pills could eventually become the primary way that obesity would be treated, and that oral drugs could have a larger market share than shots.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rh-stock-sees-slew-price-target-cuts-from-wall-street-as-trump-tariffs-bite/chw8MrGRdDN">RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite</a>

While Lilly’s broader portfolio spans diabetes, cancer, and neuroscience treatments, investors remain largely focused on Mounjaro and Zepbound. 

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company expects trial results within months from a direct comparison between its oral drug Orforglipron and Novo Nordisk’s Semaglutide.

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. 

Japanese carmaker Toyota Motor (TM) announced on Thursday that it is conducting a voluntary safety recall of approximately 591,000 vehicles in the U.S. due to concerns regarding the instrument panel.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://pressroom.toyota.com/toyota-recalls-certain-toyota-and-lexus-vehicles-5/">recall </a>involves certain Toyota Venza, Crown, Crown Signia, RAV4, GR Corolla, 4Runner, Camry, Grand Highlander, Tacoma, Highlander, and certain Lexus LS, RX, and TX vehicles.The 12.3-inch display on the instrument panel may be blank at startup, reducing the ability to see certain malfunction indicators and increasing the risk of a crash, the company stated.As for a fix, Toyota and Lexus dealers will inspect the vehicle and replace parts if needed, the company said, while adding that it will inform customers by mid-November.NYSE-listed shares of Toyota traded flat at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TM">TM stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.This year, through the end of July, Toyota sold nearly 6.1 million Toyota and Lexus brand vehicles worldwide. Sales in the U.S., including Hawaii, during the period were almost 1.5 million vehicles, surpassing any other single market and marking a 6.3% year-over-year growth. In Japan, the company’s home country, the company sold only 903,694 vehicles.However, the company produced only 800,178 vehicles in the U.S. during the period, while over 1.9 million were made in Japan. Earlier this week, it was <a href="https://stocktwits.com/news-articles/equity/markets/toyota-reshapes-us-operations-under-tariff-pressure-ev-su-vs-coming-to-kentucky-lexus-es-shifts-to-japan/chwNbuKRdHb">reported</a> that Toyota plans to produce two new three-row battery electric SUVs at its Kentucky plant as part of a strategy to streamline its U.S. operations. The changes follow the Trump administration's imposition of a 25% tariff on imported cars in April—a significant increase from the previous 2.5% rate. Following negotiations, a separate agreement reduced the rate to 15% for Japanese vehicles and parts.TM stock is up 2% this year and approximately 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/applied-digital-stock-advances-on-ai-optimism-retail-momentum-builds/chwNo3dRdvH">Applied Digital Stock Advances On AI Optimism, Retail Momentum Builds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Raindrops are seen on Toyota car logo in Krakow, Poland on December 23, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Toyota Recalls Over Half A Million Vehicles In The US

The 12.3-inch display on the instrument panel may be blank at startup, which increases the risk of a crash, the company stated.

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

DFAX
Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DFAX News

DFAXDimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF